Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

1993 • 14,121 citations

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 • 4,805 citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

2002 • 3,803 citations

Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials

1999 • 2,152 citations

Surrogate End Points in Clinical Trials: Are We Being Misled?

1996 • 1,592 citations

On the receiving end—patient perception of the side-effects of cancer chemotherapy

1983 • 988 citations

Patient preferences for oral versus intravenous palliative chemotherapy.

1997 • 922 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument

1995 • 713 citations

Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

2002 • 487 citations

End Points and United States Food and Drug Administration Approval of Oncology Drugs

2003 • 475 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Changing patient perceptions of the side effects of cancer chemotherapy

2002 • 439 citations

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

2000 • 422 citations

On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993

1996 • 394 citations

Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process

2002 • 356 citations

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

2001 • 289 citations

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1990 • 250 citations

Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

1997 • 241 citations

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

1994 • 236 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

Understanding the experience of pain in terminally ill patients

2001 • 227 citations

Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer*

2003 • 210 citations

Quality of Life in Patients With Lung Cancer

1998 • 206 citations

Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience

1999 • 199 citations

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses

1999 • 182 citations

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1995 • 175 citations

Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

2001 • 171 citations

Palliative Care*

2003 • 158 citations

Dyspnea in the Advanced Cancer Patient

1998 • 155 citations

NCCN Practice Guidelines for Cancer Pain.

2000 • 143 citations

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1996 • 132 citations

Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare

1988 • 129 citations

Dyspnea, Anxiety, Body Consciousness, and Quality of Life in Patients with Lung Cancer

2001 • 129 citations

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer

2004 • 123 citations

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

2002 • 110 citations

A Pilot Study of the Functional Living Index-Cancer (FLIC) Scale for the Assessment of Quality of Life for Metastatic Lung Cancer Patients

1988 • 105 citations

Unmet Analgesic Needs in Cancer Patients

1995 • 99 citations

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1995 • 95 citations

Prospective Study on Quality of Life Before and After Radical Radiotherapy in Non–Small-Cell Lung Cancer

2001 • 94 citations

Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group

2004 • 92 citations

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer

1989 • 82 citations

Quality of Life During Chemotherapy in Non-Small Cell Lung Cancer Patients

1989 • 74 citations

The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer

1995 • 69 citations

Oral topotecan: bioavailability and effect of food co-administration

1999 • 67 citations

Quality of Life in Lung Cancer Surgical Adjuvant Trials

1994 • 64 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

End-of-Life Care in Patients With Lung Cancer*

2003 • 62 citations

A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer

1997 • 60 citations

The Functional Assessment of Cancer Therapy—Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer

2004 • 50 citations

The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.

2002 • 46 citations

Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base

1993 • 44 citations

Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.

1994 • 42 citations

Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status

2004 • 41 citations

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

1985 • 41 citations

A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life

2002 • 34 citations

Single agent oral topotecan (OT) as first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: A phase II study

2000 • 33 citations

Influence of Clinical Parameters on Quality of Life During Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer: Application of a General Linear Model

2003 • 33 citations

927 A phase I and bioavailability study of oral topotecan

1995 • 31 citations

Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C

1995 • 30 citations

Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer

2004 • 29 citations

Quality of Life and the Treatment of Advanced Lung Cancer

2003 • 29 citations

Adoptive T-cell therapy.

1999 • 20 citations

Evolving role of oral chemotherapy for the treatment of patients with neoplasms.

1998 • 19 citations

Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.

2002 • 15 citations

Long-term venous access with a Hickman catheter: complications and patient satisfaction.

1990 • 15 citations

Feasibility of Oral Topotecan in Previously Untreated Patients with Small-Cell Lung Cancer Ineligible for Standard Therapy

2001 • 13 citations

Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients.

2000 • 12 citations

The evolving role of oral topotecan.

1999 • 11 citations

Feasibility of Oral Topotecan Plus Intravenous Paclitaxel in Advanced Non-Small-Cell Lung Cancer

2001 • 11 citations

Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy

2004 • 7 citations

O-59 Quality of life with single agent oral topotecan vs intravenous topotecan in patients with chemosensitive small cell lung cancer (SCLC). An international phase III study

2003 • 7 citations

P-578 Quality of life (QoL) with single agent oral topotecan vs intravenous topotecan in patients with chemosensitive small cell lung cancer (SCLC). QoL in balance

2003 • 6 citations

Response rate as criterium to evaluate chemotherapy in non-small cell lung cancer

1991 • 6 citations

Association of topotecan with improved performance status (PS) in relapsed small cell lung cancer (SCLC) patients with poor PS at baseline

2004 • 2 citations